cyc 202 has been researched along with tg 003 in 5 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (tg 003) | Trials (tg 003) | Recent Studies (post-2010) (tg 003) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 45 | 0 | 33 |
| Protein | Taxonomy | cyc 202 (IC50) | tg 003 (IC50) |
|---|---|---|---|
| Dual specificity protein kinase CLK2 | Mus musculus (house mouse) | 0.2 | |
| Dual specificity protein kinase CLK4 | Mus musculus (house mouse) | 0.015 | |
| Dual specificity protein kinase CLK1 | Mus musculus (house mouse) | 0.02 | |
| Dual specificity protein kinase CLK1 | Homo sapiens (human) | 0.064 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | 0.6172 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Mus musculus (house mouse) | 0.012 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Babault, L; Baratte, B; Bazureau, JP; Carreaux, F; Debdab, M; Eisenreich, A; Fedorov, O; Filippakopoulos, P; Hagiwara, M; Knapp, S; Lozach, O; Meijer, L; Ogawa, Y; Rauch, U; Renault, S; Soundararajan, M; Tahtouh, T | 1 |
| Bui, LC; Cariou, K; Dairou, J; Delabar, JM; Denhez, C; Dodd, RH; Gourdain, S; Janel, N; Rodrigues-Lima, F | 1 |
| Jarhad, DB; Jeong, LS; Kim, HR; Mashelkar, KK; Noh, M | 1 |
1 review(s) available for cyc 202 and tg 003
| Article | Year |
|---|---|
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Topics: Animals; Biological Products; Disease; Dyrk Kinases; Enzyme Activation; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases | 2018 |
4 other study(ies) available for cyc 202 and tg 003
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
Topics: Alternative Splicing; Animals; Aquatic Organisms; Benzodioxoles; Crystallography, X-Ray; Cyclin-Dependent Kinases; Dyrk Kinases; Endothelial Cells; Humans; Imidazolines; Microvessels; Models, Molecular; Nuclear Proteins; Phosphorylation; Porifera; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quantitative Structure-Activity Relationship; RNA Precursors; RNA-Binding Proteins; Serine-Arginine Splicing Factors; Stereoisomerism | 2011 |
Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity.
Topics: Dyrk Kinases; Enzyme Inhibitors; Humans; Hydrogen Bonding; Indoles; KB Cells; Molecular Docking Simulation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines | 2013 |